DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01431716 (ClinicalTrials.gov)	March 2011	7/9/2011	Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension	A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to EFI/ACT-385781A in Patients With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: EFI/ACT-385781A	Actelion	NULL	Completed	18 Years	N/A	All	42	Phase 3	Belgium;Canada;France;Italy;Netherlands;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01431716
(ClinicalTrials.gov)

March 2011

7/9/2011

Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension

A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to EFI/ACT-385781A in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Drug: EFI/ACT-385781A

Actelion

NULL

Completed

18 Years

N/A

All

Phase 3

Belgium;Canada;France;Italy;Netherlands;Spain